Increased risk of SARS-CoV-2 infection in staff working across different care homes: enhanced CoVID-19 outbreak investigations in London care Homes.


Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 19 07 2020
accepted: 25 07 2020
pubmed: 1 8 2020
medline: 6 10 2020
entrez: 1 8 2020
Statut: ppublish

Résumé

Care homes have been disproportionately affected by the COVID-19 pandemic and continue to suffer large outbreaks even when community infection rates are declining, thus representing important pockets of transmission. We assessed occupational risk factors for SARS-CoV-2 infection among staff in six care homes experiencing a COVID-19 outbreak during the peak of the pandemic in London, England. Care home staff were tested for SARS-COV-2 infection by RT-PCR and asked to report any symptoms, their contact with residents and if they worked in different care homes. Whole genome sequencing (WGS) was performed on RT-PCR positive samples. In total, 53 (21%) of 254 staff were SARS-CoV-2 positive but only 12/53 (23%) were symptomatic. Among staff working in a single care home, SARS-CoV-2 positivity was 15% (2/13), 16% (7/45) and 18% (30/169) in those reporting no, occasional and regular contact with residents. In contrast, staff working across different care homes (14/27, 52%) had a 3.0-fold (95% CI, 1.9-4.8; P<0.001) higher risk of SARS-CoV-2 positivity than staff working in single care homes (39/227, 17%). WGS identified SARS-CoV-2 clusters involving staff only, including some that included staff working across different care homes. SARS-CoV-2 positivity was significantly higher among staff working across different care homes than those who were working in the same care home. We found local clusters of SARS-CoV-2 infection between staff only, including those with minimal resident contact. Infection control should be extended for all contact, including those between staff, whilst on care home premises.

Sections du résumé

BACKGROUND BACKGROUND
Care homes have been disproportionately affected by the COVID-19 pandemic and continue to suffer large outbreaks even when community infection rates are declining, thus representing important pockets of transmission. We assessed occupational risk factors for SARS-CoV-2 infection among staff in six care homes experiencing a COVID-19 outbreak during the peak of the pandemic in London, England.
METHODS METHODS
Care home staff were tested for SARS-COV-2 infection by RT-PCR and asked to report any symptoms, their contact with residents and if they worked in different care homes. Whole genome sequencing (WGS) was performed on RT-PCR positive samples.
RESULTS RESULTS
In total, 53 (21%) of 254 staff were SARS-CoV-2 positive but only 12/53 (23%) were symptomatic. Among staff working in a single care home, SARS-CoV-2 positivity was 15% (2/13), 16% (7/45) and 18% (30/169) in those reporting no, occasional and regular contact with residents. In contrast, staff working across different care homes (14/27, 52%) had a 3.0-fold (95% CI, 1.9-4.8; P<0.001) higher risk of SARS-CoV-2 positivity than staff working in single care homes (39/227, 17%). WGS identified SARS-CoV-2 clusters involving staff only, including some that included staff working across different care homes.
CONCLUSIONS CONCLUSIONS
SARS-CoV-2 positivity was significantly higher among staff working across different care homes than those who were working in the same care home. We found local clusters of SARS-CoV-2 infection between staff only, including those with minimal resident contact. Infection control should be extended for all contact, including those between staff, whilst on care home premises.

Identifiants

pubmed: 32735893
pii: S0163-4453(20)30508-9
doi: 10.1016/j.jinf.2020.07.027
pmc: PMC7387283
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

621-624

Subventions

Organisme : Medical Research Council
ID : MC_PC_19027
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Références

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10625-30
pubmed: 18647829
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Public Health (Oxf). 2008 Mar;30(1):99-102
pubmed: 18208814
J Am Geriatr Soc. 2020 Aug;68(8):1657-1660
pubmed: 32338767
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
J Infect. 2020 Sep;81(3):411-419
pubmed: 32504743
PLoS One. 2019 Sep 24;14(9):e0222321
pubmed: 31550261
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):377-381
pubmed: 32240128
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971

Auteurs

Shamez N Ladhani (SN)

Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Paediatric Infectious Diseases Research Group, St. George's University of London, UK. Electronic address: shamez.ladhani@phe.gov.uk.

J Yimmy Chow (JY)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Roshni Janarthanan (R)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Jonathan Fok (J)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Emma Crawley-Boevey (E)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Amoolya Vusirikala (A)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Elena Fernandez (E)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Marina Sanchez Perez (MS)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Suzanne Tang (S)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Kate Dun-Campbell (K)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Edward Wynne-Evans (E)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Anita Bell (A)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Bharat Patel (B)

London Health Protection team, National Infection Service, Public Health England, London, UK.

Zahin Amin-Chowdhury (Z)

Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.

Felicity Aiano (F)

Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.

Karthik Paranthaman (K)

Field Service, National Infection Service, Public Health England.

Thomas Ma (T)

Field Service, National Infection Service, Public Health England.

Maria Saavedra-Campos (M)

Field Service, National Infection Service, Public Health England.

Richard Myers (R)

Infectious Disease Informatics, Public Health England, London, UK.

Joanna Ellis (J)

Virus Reference department, Public Health England, London, UK.

Angie Lackenby (A)

Virus Reference department, Public Health England, London, UK.

Robin Gopal (R)

Virus Reference department, Public Health England, London, UK.

Monika Patel (M)

Virus Reference department, Public Health England, London, UK.

Meera Chand (M)

Antimicrobial Resistance and Hospital Acquired Infection Department, Public Health England, London, UK.

Kevin Brown (K)

Virus Reference department, Public Health England, London, UK.

Susan Hopkins (S)

Antimicrobial Resistance and Hospital Acquired Infection Department, Public Health England, London, UK.

CoG Consortium (C)

COVID-19 Genomics UK Consortium (https://www.cogconsortium.uk/).

Nandini Shetty (N)

Virus Reference department, Public Health England, London, UK.

Maria Zambon (M)

Virus Reference department, Public Health England, London, UK.

Mary E Ramsay (ME)

Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH